Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

oncoprescribe-top

Advertisement

Tag: Paroxsymal Nocturnal Hemoglobinuria

ULTOMIRIS® (Ravulizumab-cwvz)

December 27, 2018April 5, 2020 RR

The FDA on December 21, 2018 approved ULTOMIRIS® for adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). ULTOMIRIS® is a product of Alexion Pharmaceuticals, Inc.

Ad 1

source: oncoprescribe.com

Advertisement

Ad 2

”Dictionary-of-Cancer-Terms-in-OncoPrescribe”/

Advertisement

Ad 3

OncoPrescribe

Advertisement

Ad 4

Immunization Schedule

Advertisement

  • HELP
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved